[A19-03] Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51
Last updated 21.03.2019
Project no.:
A19-03
Commission:
Commission awarded on 07.01.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy
Now hint of minor added benefit after pretreatment with a conventional synthetic DMARD. Added benefit still not proven after pretreatment with a biological DMARD
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-51 | Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-02-21 A G-BA decision was published.